Effect of Eplerenone, a Selective Aldosterone Blocker, on Blood Pressure, Serum and Macrophage Oxidative Stress, and Atherosclerosis in Apolipoprotein E–Deficient Mice
Authors:
- Shlomo KeidarSKShlomo Keidar
- Tony HayekTHTony Hayek
- Marielle KaplanMKMarielle Kaplan
- Elsa PavlotzkyEPElsa Pavlotzky
- Shadi HamoudSHShadi Hamoud
- Raymond ColemanRCRaymond Coleman
- Michael AviramMAMichael Aviram
- 1 June 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 41 (6) , 955-963
Abstract
Oxidative stress is involved in the pathogenesis of atherosclerosis, and angiotensin II (AT-II) induces oxidative stress and enhances atherogenesis. Aldosterone, which has an important role in the pathology of heart failure, has recently been implicated as a mediator of AT-II biologic activities. In this study, we analyzed whether administration of the selective aldosterone blocker eplerenone to atherosclerotic apolipoprotein E–deficient (E0) mice would affect their oxidative status and atherogenesis. Apolipoprotein E–deficient mice were administered chow containing eplerenone (200 mg/kg/day) for 3 months. Blood pressure, serum and macrophage oxidative status, and aortic atherosclerotic lesion area were evaluated in mice treated with eplerenone compared with untreated mice. Eplerenone administration significantly decreased systolic and diastolic blood pressure by 12% and 11%, respectively, compared with untreated mice. Serum susceptibility to lipid peroxidation decreased by as much as 26%, and serum paraoxonase activity increased by 28% in eplerenone-treated mice compared with untreated mice. Peritoneal macrophages from eplerenone-treated mice contained reduced levels of lipid peroxides, and their macrophage oxidation of low-density lipoprotein (LDL) and superoxide ion release were significantly reduced (by 17% and 43%, respectively), compared to untreated mice. Daily injections of AT-II (0.1 mL, 10− 7 M) during the final 3 weeks of the study in eplerenone-treated mice substantially attenuated the eplerenone-mediated reduction in macrophage superoxide release and LDL oxidation. Finally, the atherosclerotic lesion area in aortas of eplerenone-treated mice was significantly reduced (by 35%) versus untreated mice, and this effect was reversed by AT-II. Administration of the selective aldosterone blocker eplerenone significantly reduced oxidative stress and atherosclerosis progression in E0 mice. These data suggest that aldosterone could have a significant pro-oxidative role in the pathogenesis of atherosclerosis.Keywords
This publication has 49 references indexed in Scilit:
- AtherosclerosisNature, 2000
- Oxidized Low Density Lipoprotein: Atherogenic and Proinflammatory Characteristics during Macrophage Foam Cell Formation. An Inhibitory Role for Nutritional Antioxidants and Serum ParaoxonaseClinical Chemistry and Laboratory Medicine (CCLM), 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase ActivitiesArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.Journal of Clinical Investigation, 1998
- Low Density Lipoprotein Oxidation and Its Pathobiological SignificanceJournal of Biological Chemistry, 1997
- Lewis A. Conner Memorial LectureCirculation, 1997
- The role of oxidized lipoproteins in atherogenesisFree Radical Biology and Medicine, 1996
- Atherosclerosis: Basic MechanismsCirculation, 1995
- Mechanisms of oxidation, antioxidants, and atherosclerosisCurrent Opinion in Lipidology, 1994